The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Short Bowel Syndrome (SBS) Market Research Report 2025
Synopsis
Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.
The global Short Bowel Syndrome (SBS) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
This report aims to provide a comprehensive presentation of the global market for Short Bowel Syndrome (SBS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short Bowel Syndrome (SBS).
Report Scope
The Short Bowel Syndrome (SBS) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Short Bowel Syndrome (SBS) market comprehensively. Regional market sizes, concerning products by Type, by Sale Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short Bowel Syndrome (SBS) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Sale Channel, and by regions.
Market Segmentation
By Company
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
Segment by Type
Oral Route
Parental Route
Segment by Sale Channel
Hospitals
Clinics
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Sale Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Sale Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Short bowel syndrome (SBS) is a metabolic disorder occurs when the portion of the small intestine is not functioning or removed through surgery due to digestive illness. SBS is caused by lack of function of the small intestine. This results in malabsorption, diarrhea, steatorrhea, fluid and electrolyte disturbances, and malnutrition.
The global Short Bowel Syndrome (SBS) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
During 2017, the parental route segment accounted for the major shares and dominated the SBS market. Factors such as the rapid action mechanism of the drug and the prolonged action result contribute to the growth of this market segment in the coming years. In the parental route, the drug is administered intravenously, subcutaneously, intrathecally, or through intramuscular routes and is applied when the oral route of drug administration is ineffective.
This report aims to provide a comprehensive presentation of the global market for Short Bowel Syndrome (SBS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Short Bowel Syndrome (SBS).
Report Scope
The Short Bowel Syndrome (SBS) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Short Bowel Syndrome (SBS) market comprehensively. Regional market sizes, concerning products by Type, by Sale Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Short Bowel Syndrome (SBS) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Sale Channel, and by regions.
Market Segmentation
By Company
Merck
Takeda
Emmaus Medical
Ardelyx
Naia Pharmaceuticals
Nutrinia
OxThera
Sancilio Pharmaceuticals
Zealand Pharma
Segment by Type
Oral Route
Parental Route
Segment by Sale Channel
Hospitals
Clinics
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Sale Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Short Bowel Syndrome (SBS) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Sale Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Short Bowel Syndrome (SBS) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral Route
1.2.3 Parental Route
1.3 Market by Sale Channel
1.3.1 Global Short Bowel Syndrome (SBS) Market Growth by Sale Channel: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Short Bowel Syndrome (SBS) Market Perspective (2019-2030)
2.2 Short Bowel Syndrome (SBS) Growth Trends by Region
2.2.1 Global Short Bowel Syndrome (SBS) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Short Bowel Syndrome (SBS) Historic Market Size by Region (2019-2024)
2.2.3 Short Bowel Syndrome (SBS) Forecasted Market Size by Region (2025-2030)
2.3 Short Bowel Syndrome (SBS) Market Dynamics
2.3.1 Short Bowel Syndrome (SBS) Industry Trends
2.3.2 Short Bowel Syndrome (SBS) Market Drivers
2.3.3 Short Bowel Syndrome (SBS) Market Challenges
2.3.4 Short Bowel Syndrome (SBS) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Short Bowel Syndrome (SBS) Players by Revenue
3.1.1 Global Top Short Bowel Syndrome (SBS) Players by Revenue (2019-2024)
3.1.2 Global Short Bowel Syndrome (SBS) Revenue Market Share by Players (2019-2024)
3.2 Global Short Bowel Syndrome (SBS) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Short Bowel Syndrome (SBS) Revenue
3.4 Global Short Bowel Syndrome (SBS) Market Concentration Ratio
3.4.1 Global Short Bowel Syndrome (SBS) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Short Bowel Syndrome (SBS) Revenue in 2023
3.5 Short Bowel Syndrome (SBS) Key Players Head office and Area Served
3.6 Key Players Short Bowel Syndrome (SBS) Product Solution and Service
3.7 Date of Enter into Short Bowel Syndrome (SBS) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Short Bowel Syndrome (SBS) Breakdown Data by Type
4.1 Global Short Bowel Syndrome (SBS) Historic Market Size by Type (2019-2024)
4.2 Global Short Bowel Syndrome (SBS) Forecasted Market Size by Type (2025-2030)
5 Short Bowel Syndrome (SBS) Breakdown Data by Sale Channel
5.1 Global Short Bowel Syndrome (SBS) Historic Market Size by Sale Channel (2019-2024)
5.2 Global Short Bowel Syndrome (SBS) Forecasted Market Size by Sale Channel (2025-2030)
6 North America
6.1 North America Short Bowel Syndrome (SBS) Market Size (2019-2030)
6.2 North America Short Bowel Syndrome (SBS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Short Bowel Syndrome (SBS) Market Size by Country (2019-2024)
6.4 North America Short Bowel Syndrome (SBS) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Short Bowel Syndrome (SBS) Market Size (2019-2030)
7.2 Europe Short Bowel Syndrome (SBS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Short Bowel Syndrome (SBS) Market Size by Country (2019-2024)
7.4 Europe Short Bowel Syndrome (SBS) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Short Bowel Syndrome (SBS) Market Size (2019-2030)
8.2 Asia-Pacific Short Bowel Syndrome (SBS) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Short Bowel Syndrome (SBS) Market Size by Region (2019-2024)
8.4 Asia-Pacific Short Bowel Syndrome (SBS) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Short Bowel Syndrome (SBS) Market Size (2019-2030)
9.2 Latin America Short Bowel Syndrome (SBS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Short Bowel Syndrome (SBS) Market Size by Country (2019-2024)
9.4 Latin America Short Bowel Syndrome (SBS) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Short Bowel Syndrome (SBS) Market Size (2019-2030)
10.2 Middle East & Africa Short Bowel Syndrome (SBS) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Short Bowel Syndrome (SBS) Market Size by Country (2019-2024)
10.4 Middle East & Africa Short Bowel Syndrome (SBS) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Short Bowel Syndrome (SBS) Introduction
11.1.4 Merck Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Takeda
11.2.1 Takeda Company Detail
11.2.2 Takeda Business Overview
11.2.3 Takeda Short Bowel Syndrome (SBS) Introduction
11.2.4 Takeda Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.2.5 Takeda Recent Development
11.3 Emmaus Medical
11.3.1 Emmaus Medical Company Detail
11.3.2 Emmaus Medical Business Overview
11.3.3 Emmaus Medical Short Bowel Syndrome (SBS) Introduction
11.3.4 Emmaus Medical Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.3.5 Emmaus Medical Recent Development
11.4 Ardelyx
11.4.1 Ardelyx Company Detail
11.4.2 Ardelyx Business Overview
11.4.3 Ardelyx Short Bowel Syndrome (SBS) Introduction
11.4.4 Ardelyx Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.4.5 Ardelyx Recent Development
11.5 Naia Pharmaceuticals
11.5.1 Naia Pharmaceuticals Company Detail
11.5.2 Naia Pharmaceuticals Business Overview
11.5.3 Naia Pharmaceuticals Short Bowel Syndrome (SBS) Introduction
11.5.4 Naia Pharmaceuticals Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.5.5 Naia Pharmaceuticals Recent Development
11.6 Nutrinia
11.6.1 Nutrinia Company Detail
11.6.2 Nutrinia Business Overview
11.6.3 Nutrinia Short Bowel Syndrome (SBS) Introduction
11.6.4 Nutrinia Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.6.5 Nutrinia Recent Development
11.7 OxThera
11.7.1 OxThera Company Detail
11.7.2 OxThera Business Overview
11.7.3 OxThera Short Bowel Syndrome (SBS) Introduction
11.7.4 OxThera Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.7.5 OxThera Recent Development
11.8 Sancilio Pharmaceuticals
11.8.1 Sancilio Pharmaceuticals Company Detail
11.8.2 Sancilio Pharmaceuticals Business Overview
11.8.3 Sancilio Pharmaceuticals Short Bowel Syndrome (SBS) Introduction
11.8.4 Sancilio Pharmaceuticals Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.8.5 Sancilio Pharmaceuticals Recent Development
11.9 Zealand Pharma
11.9.1 Zealand Pharma Company Detail
11.9.2 Zealand Pharma Business Overview
11.9.3 Zealand Pharma Short Bowel Syndrome (SBS) Introduction
11.9.4 Zealand Pharma Revenue in Short Bowel Syndrome (SBS) Business (2019-2024)
11.9.5 Zealand Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
